ABCD-GENE Score Stratifying Risk-Benefit Profile of Clopidogrel-Aspirin Therapy in Ischemic Stroke Within 24-72 Hours.

Although the population of poor metabolizers was relatively small, and the differences in clopidogrel efficacy outcomes among patients with an ABCD-GENE score >24 did not reach statistical significance, yet the trend toward potential risk of stroke with dual antiplatelet therapy was noted in this subgroup.

also in 111,027 other papers